Cchek has been validated with 14 cancer types:

  • Breast Cancer Ribbon Breast Cancer
  • Lung Cancer Ribbon Lung Cancer
  • Colon Cancer Ribbon Colon Cancer
  • Prostate Cancer Ribbon Prostate Cancer
  • Melanoma Ribbon Melanoma
  • Ovarian Cancer Ribbon Ovarian Cancer
  • Liver Cancer Ribbon Liver Cancer
  • Thyroid Cancer Ribbon Thyroid Cancer
  • Pancreative Cancer Ribbon Pancreative Cancer
  • Appendiceal Cancer Ribbon Appendiceal Cancer
  • Uterine Cancer Ribbon Uterine Cancer
  • Osteosarcoma Ribbon Osteosarcoma
  • Leiomyosarcoma Ribbon Leiomyosarcoma
  • Lipsarcoma Ribbon Lipsarcoma
  • Vulvar Cancer Ribbon Vulvar Cancer

Testing

Total patients tested: 315*

Cancer patients: 225

Healthy patients: 87

*Pre-treatment and post-treatment biopsy verified samples tested with varying protocols

Preliminary Results


**88 patient samples tested in an unblinded manner; includes 59 biopsy verified cancers across 14 different types of cancer

Results were analyzed using artificial intelligence and most recent protocols.


Scientific criteria for evaluating diagnostics:

Sensitivity (Accuracy) measures how good a test is at detecting cancer

Specificity (Reliability) measures how good a test is at distinguishing cancer patients from healthy patients

What is Artificial Intelligence?

Artificial intelligence (AI) refers to the ability of a computer system to simulate human intelligence, with the capacity to perform a greater number of concurrent analyses more quickly than a human typically can.

ITUS is developing a software application using a proprietary neural network, an AI system that focuses on complex pattern recognition. Our neural network has been specifically trained to distinguish between the immunological responses of cancer patients and healthy patients, relying on up to 13 quantitative parameters to analyze test results. As more and more samples are processed, the neural network learns to make more accurate and reliable distinctions. In addition to this enhanced efficiency, the neural network is not subject to human error or bias, which may lead to better results.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

ITUS Corporation Successfully Completes $3.6 Million Public Offering

Read More...

ITUS Corporation Announces Pricing of Public Offering of up to 3.5 million shares of Common Stock

Read More...

ITUS Corporation Announces Proposed Public Offering of Common Stock

Read More...

Worldwide Cancer Incidences